Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Biopharma Segment by Quarter
Biopharma Segment — Acquired in-process R&D (IPR&D) ($M) ($M)
Pfizer Biopharma Segment: $16M in Q2 2026, up 700.0% from a year earlier.
Latest, Q2 2026
16
Period ended Jun 28, 2026
Change on a year earlier
+700.0%
2 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
6
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Reported in Form 10-Q / 10-K Note 17 — Segment Reporting (ASU 2023-07 Significant Segment Expenses).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biopharma Segment — Acquired in-process R&D (IPR&D) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 16 | +700.0% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 137 | +1,422.2% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 62 | -29.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 40 | +207.7% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 2 | -71.4% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 30, 2025 | 9 | – | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 88 | – | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 13 | – | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 7 | – | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 0 | – | Form 10-Q (filed 2025-05-05) ↗ |
Cite this data
StockData. (2026). Pfizer Biopharma Segment ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-iprd-bio
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.